Skip to content
value.today
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

Total raised
$46 M
1 round on record
Latest round
$46 M
Oct 2018
First round on record
Oct 2018
Today
Went public
See the company page

Sana Biotechnology, Inc. is listed today as Sana Biotechnology, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Sana Biotechnology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2019$821 MIssued in a merger or acquisition$250 million to $1 billion

Sana Biotechnology, Inc.: Private sale, Feb 2019

Investors in this round

40 investors had bought by the notice of Jun 26, 2020: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 21 investors are named for Sana Biotechnology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$821 M of $821 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them, other: Series A-2 Preferred Stock; Series B Preferred Stock; Common Stock issuable upon conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James J. MacDonald · Executive Officer
  • Nathan D. Hardy · Executive Officer
  • Steven D. Harr · Executive Officer, Director
  • Donald J. Payan · Director
  • Douglas J. Cole · Director
  • Geoffrey J. von Maltzahn · Director
  • Hans J. Bishop · Director
  • Mary Agnes J. Wilderotter · Director
  • Patrick J. Yang · Director
  • Richard J. Mulligan · Director
  • Robert J. Nelsen · Director
  • Stephen J. Knight · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven D. Harr, President & Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 26, 2020. Read the notice at the SEC.

equitySEC
Oct 2018$46 MNo. 1$10 to $50 million

Sana Biotechnology, Inc.: Raise no. 1, Oct 2018

Investors in this round

8 investors had bought by the notice of Jun 26, 2020: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 21 investors are named for Sana Biotechnology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$46 M of $46 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them, other: Series A-1 Preferred Stock; Common Stock issuable upon conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James J. MacDonald · Executive Officer
  • Nathan D. Hardy · Executive Officer
  • Steven D. Harr · Executive Officer, Director
  • Donald J. Payan · Director
  • Douglas J. Cole · Director
  • Geoffrey J. von Maltzahn · Director
  • Hans J. Bishop · Director
  • Mary Agnes J. Wilderotter · Director
  • Patrick J. Yang · Director
  • Richard J. Mulligan · Director
  • Robert J. Nelsen · Director
  • Stephen J. Knight · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven D. Harr, President & Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 26, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Sana Biotechnology, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2020

That is all the official record says: Sana Biotechnology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Sana Biotechnology, Inc. are on record.

Investors#

21 named in official filings. Open an investor to see everything it has backed.

Investors in Sana Biotechnology, Inc.
InvestorKindAmountRoundRoleSource
ARCH Venture Fund IX, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Fund IX Overage, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Fund X, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Fund X Overage, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners IX, LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners IX Overage, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners X, LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners X, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners X Overage, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Flagship Pioneering Fund VI General Partner LLCFund or asset managernot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Flagship Pioneering Fund VI, L.P.Fund or asset managernot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Flagship Pioneering, LLCFund or asset managernot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Flagship VentureLabs V LLCVenture capitalnot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Flagship VentureLabs V Manager LLCVenture capitalnot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Flagship Ventures Fund V General Partner LLCVenture capitalnot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Flagship Ventures Fund V, L.P.Venture capitalnot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Flagship V VentureLabs Rx Fund, L.P.Venture capitalnot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Geoffrey Von MaltzahnPersonnot statednot statedHeld Series A-2 preferred stock, director (Form 3, 2021)SEC Form 3
Hans Edgar BishopPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock, director (Form 3, 2021)SEC Form 3
James J. MacDonaldPersonnot statednot statedHeld Series A-1 preferred stock (Form 3, 2021)SEC Form 3
Steve HarrPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.

Largest shareholders today

Institutions holding Sana Biotechnology, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sana Biotechnology, Inc.
NameRoleNamed in
James J. MacDonaldExecutive officerJun 2020
Nathan D. HardyExecutive officerJun 2020
Steven D. HarrExecutive officerJun 2020
Donald J. PayanDirectorJun 2020
Douglas J. ColeDirectorJun 2020
Geoffrey J. von MaltzahnDirectorJun 2020
Hans J. BishopDirectorJun 2020
Mary Agnes J. WilderotterDirectorJun 2020
Patrick J. YangDirectorJun 2020
Richard J. MulliganDirectorJun 2020
Robert J. NelsenDirectorJun 2020
Stephen J. KnightDirectorJun 2020
Steven D. HarrDirectorJun 2020

About

Biotechnology company.

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.